RASSF1A and p16 promoter methylation and treatment response in chronic hepatitis C genotype 1b patients treated with pegylated interferon/ribavirin

Authors

  • Nikola S. Kokanov Vinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, Laboratory for Radiobiology and Molecular Genetics, University of Belgrade, Mike Petrovića Alasa 12-14, Belgrade, Serbia https://orcid.org/0000-0002-2380-2028
  • Milena M. Krajnović Vinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, Laboratory for Radiobiology and Molecular Genetics, University of Belgrade, Mike Petrovića Alasa 12-14, Belgrade, Serbia https://orcid.org/0000-0001-5638-2042
  • Snežana P. Jovanović-Ćupić Vinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, Laboratory for Radiobiology and Molecular Genetics, University of Belgrade, Mike Petrovića Alasa 12-14, Belgrade, Serbia https://orcid.org/0000-0002-3389-7278
  • Bojana R. Kožik Vinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, Laboratory for Radiobiology and Molecular Genetics, University of Belgrade, Mike Petrovića Alasa 12-14, Belgrade, Serbia https://orcid.org/0000-0002-2983-4151
  • Nina M. Petrović Vinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, Laboratory for Radiobiology and Molecular Genetics, University of Belgrade, Mike Petrovića Alasa 12-14, Belgrade, Serbia https://orcid.org/0000-0003-2503-1228
  • Ana M. Božović Vinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, Laboratory for Radiobiology and Molecular Genetics, University of Belgrade, Mike Petrovića Alasa 12-14, Belgrade, Serbia https://orcid.org/0000-0002-6487-6365
  • Vesna Lj. Mandušić Vinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, Laboratory for Radiobiology and Molecular Genetics, University of Belgrade, Mike Petrovića Alasa 12-14, Belgrade, Serbia https://orcid.org/0000-0002-2221-3707

DOI:

https://doi.org/10.2298/ABS211208004K

Keywords:

Hepatitis C virus, DNA methylation, RASSF1A, p16, biomarkers

Abstract

Paper description:

  • Patients with chronic hepatitis C genotype 1b would benefit from early detection of molecular markers predicting the response to therapy with pegylated interferon/ribavirin.
  • We investigated whether the methylation status of RASSF1A and p16 genes combined with host factors affects the response to therapy and disease progression.
  • Simultaneous presence of RASSF1A methylation and the IL28B CC genotype was significantly related to a sustained virologic response and methylation of the RASSF1A
  • The methylation status of RASSF1A and IL28B rs12979860 polymorphism could potentially help predict the response to therapy.

Abstract: Prevention of chronic hepatitis C (CHC) and its complications is based on antiviral therapy and early detection of reliable molecular markers in persons under risk. We investigated whether the methylation status of RASSF1A and p16 genes, alone or in combination with host and viral factors, affects the response to therapy with pegylated interferon/ribavirin (PEG-IFN/RBV). Methylation-specific polymerase chain reaction (MSP) was used to determine the methylation status of the target promoter sequences of RASSF1A and p16 in circulating-free DNA from the peripheral blood of 49 patients with CHC genotype 1b. The methylation status of the examined genes did not affect the response to therapy. However, the simultaneous presence of either RASSF1A or p16 methylation and the CC genotype of IL28B was significantly related to a sustained virologic response (P=0.009 and P=0.032, respectively). After Bonferroni correction, only the result concerning the RASSF1A gene remained significant (P<0.0125). Methylation of RASSF1A was associated with the CC genotype of the IL28B gene (P=0.024) and a higher viral load (≥400 000 IU/mL, P=0.009). Our results suggest that combined analysis of RASSF1A gene methylation and IL28B rs12979860 polymorphism could potentially help in the prediction of therapy response in CHC genotype 1b patients.

Downloads

Download data is not yet available.

References

Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61:S58‐68. https://doi.org/10.1016/j.jhep.2014.07.012

Raimondi S, Bruno S, Mondeli MU, Maisonneuve. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol. 2009;50:1142-54. https://doi.org/10.1016/j.jhep.2009.01.019

Simonovic-Babic J, Bojovic K, Fabri M, Cvejic T, Svorcan P, Nozic D, Jovanovic M,Skrbic R, Stojiljkovic MP, Mijailovic Z. Real-life data on the efficacy and safety of ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in the patients with genotype 1 chronic hepatitis C virus infection in Serbia. Vojnosanitetski pregled. 2019;76:531-536. https://doi.org/10.2298/VSP170727186S

EASL International Consensus Conference on Hepatitis C: Consensus statement. J Hepatol. 1999;30:956-61. https://doi.org/10.1016/S0168-8278(99)80154-8

Bartenschlager R, Baumert TF, Bukh J, Houghton M, Lemon SM, Lindenbach BD, Lohmann V, Moradpour D, Pietschmann T, Rice CM, Thimme R, Wakita T. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. Virus Res. 2018;248:53‐62. https://doi.org/10.1016/j.virusres.2018.02.016

Hamdane N, Jühling F, Crouchet E, El Saghire H, Thumann C, Oudot MA, Bandiera S, Saviano A, Ponsolles C, Roca Suarez AA, Li S, Fujiwara N, Ono A, Davidson I, Bardeesy N, Schmidl C, Bock C, Schuster C, Lupberger J, Habersetzer F, Doffoël M, Piardi T, Sommacale D, Imamura M, Uchida T, Ohdan H, Aikata H, Chayama K, Boldanova T, Pessaux P, Fuchs BC, Hoshida Y, Zeisel MB, Duong FHT, Baumert TF. HCV-Induced Epigenetic Changes Associated with Liver Cancer Risk Persist After Sustained Virologic Response. Gastroenterology. 2019;156:2313-29. https://doi.org/10.1053/j.gastro.2019.02.038

Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41-52. https://doi.org/10.1056/NEJM200107053450107

N Zekri AR, Raafat AM, Elmasry S, Bahnassy AA, Saad Y, Dabaon HA, El-Kassas M, Shousha HI, Nassar AA, El-Dosouky MA, Hussein N. Promotor methylation: does it affect response to therapy in chronic hepatitis C (G4) or fibrosis? Ann Hepatol. 2014;13:518‐24. https://doi.org/10.1016/S1665-2681(19)31251-7

Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100-4. https://doi.org/10.1038/ng.447

Sugiyama M, Tanaka Y, Nakanishi M, Mizokami M. Novel findings for the development of drug therapy for various liver diseases: Genetic variation in IL-28B is associated with response to the therapy for chronic hepatitis C. J Pharmacol Sci. 2011;115:263‐9. https://doi.org/10.1254/jphs.10R15FM

Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003;4(1):63-8. https://doi.org/10.1038/ni873

Zekri Ael-R, Nassar AA, El-Din El-Rouby MN, Shousha HI, Barakat AB, El-Desouky ED, Zayed NA, Ahmed OS, El-Din Youssef AS, Kaseb AO, Abd El-Aziz AO, Bahnassy AA. Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with increasing DNA promoter methylation. Asian Pac J Cancer Prev. 2014;14(11):6721‐6. https://doi.org/10.7314/APJCP.2013.14.11.6721

Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042‐54. https://doi.org/10.1056/NEJMra023075

Huang JZ, Xia SS, Ye QF, Jiang HY, Chen ZH. Effects of p16 gene on biological behaviours in hepatocellular carcinoma cells. World J Gastroenterol. 2003;9:84‐8. https://doi.org/10.3748/wjg.v9.i1.84

Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol. 2003;163:1371‐8. https://doi.org/10.1016/S0002-9440(10)63495-5

Zang JJ, Xie F, Xu JF, Qin YY, Shen RX, Yang JM, He J. P16 gene hypermethylation and hepatocellular carcinoma: a systematic review and meta-analysis. World J Gastroenterol. 2011;17:3043‐8. https://doi.org/10.3748/wjg.v17.i25.3043

Mohamed NA, Swify EM, Amin NF, Soliman MM, Tag-Eldin LM, Elsherbiny NM. Is serum level of methylated RASSF1A valuable in diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis C? Arab J Gastroenterol. 2012;13:111‐5. https://doi.org/10.1016/j.ajg.2012.06.009

Dubois F, Bergot E, Zalcman G, Levallet G. RASSF1A, puppeteer of cellular homeostasis, fights tumorigenesis, and metastasis-an updated review. Cell Death Dis. 2019;10:928. https://doi.org/10.1038/s41419-019-2169-x

Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res. 2001;264:42‐55. https://doi.org/10.1006/excr.2000.5149

Wong IH, Lo YM, Zhang J, Liew CT, Ng MH, Wong N, Lai PB, Lau WY, Hjelm NM, Johnson PJ. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 1999;59:71‐3.

Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A, Klocker H, Goebel G, Widschwendter M. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res. 2005;65:1141‐5. https://doi.org/10.1158/0008-5472.CAN-04-2438

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24. https://doi.org/10.1126/scitranslmed.3007094

Mann J, Reeves HL, Feldstein AE. Liquid biopsy for liver diseases. Gut. 2018;67:2204‐12. https://doi.org/10.1136/gutjnl-2017-315846

Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289-93. https://doi.org/10.1002/hep.510240201

Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Sato K, Tsuda F, Miyakawa Y, Mayumi M. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol. 1992;73:673-9. https://doi.org/10.1099/0022-1317-73-3-673

Okamoto H, Mishiro S. Genetic heterogeneity of hepatitis C virus. Intervirology. 1994;37:68-76. https://doi.org/10.1159/000150360

Alestig E, Arnholm B, Eilard A, Lagging M, Nilsson S, Norkrans G, Wahlberg T, Wejstål R, Westin J, Lindh M. Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection. BMC Infect Dis. 2011;11:124. https://doi.org/10.1186/1471-2334-11-124

Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821-6. https://doi.org/10.1073/pnas.93.18.9821

Wang YC, Yu ZH, Liu C, Xu LZ, Yu W, Lu J, Zhu RM, Li GL, Xia XY, Wei XW, Ji HZ, Lu H, Gao Y, Gao WM, Chen LB. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. World J Gastroenterol. 2008;14:3074-80. https://doi.org/10.3748/wjg.14.3074

Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399‐401. https://doi.org/10.1038/nature08309

Jovanovic-Cupic S, Petrovic N, Krajnovic M, Bundalo M, Kokanov N, Bozovic A, Stamenkovic G. Role of host and viral factors and genetic variation of IL28B on therapy outcome in patients with chronic hepatitis C genotype 1b from Serbia. Genetics & Applications. 2019;3:36-41. https://doi.org/10.31383/ga.vol3iss1pp36-41

Rinaldi L, Nevola R, Franci G, Perrella A, Corvino G, Marrone A, Berretta M, Morone MV, Galdiero M, Giordano M, Adinolfi LE, Sasso FC. Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics. Cancers (Basel). 2020;12:1351. https://doi.org/10.3390/cancers12061351

Domowitz T, M Gal-Tanamy. Tracking Down the Epigenetic Footprint of HCV-Induced Hepatocarcinogenesis. J Clin Med. 2021;10:551. https://doi.org/10.3390/jcm10030551

Kaneto H, Sasaki S, Yamamoto H, Itoh F, Toyota M, Suzuki H, Ozeki I, Iwata N, Ohmura T, Satoh T, Karino Y, Satoh T, Toyota J, Satoh M, Endo T, Omata M, Imai K. Detection of hypermethylation of the p16(INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut. 2001;48:372‐7.

Shivakumar L, Minna J, Sakamaki T, Pestell R, White MA. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol. 2002;22:4309‐18. https://doi.org/10.1128/MCB.22.12.4309-4318.2002

El-Sabakawy K, Assaf R, Arafa L, Shiha O, El-Beeh S. Evaluation of hypermethylation of ras association domain family-1a and glutathione s-transferase protein-1 genes as diagnostic marker for hepatocellular carcinoma. ZUMJ. 2015;21:1-13. https://doi.org/10.21608/zumj.2015.4524

Mostafa WSEM, Al-Dahr MHS, Omran DAH, Abdullah ZF, Elmasry SH, Ibrahim MN. Influence of some methylated hepatocarcinogenesis-related genes on the response to antiviral therapy and development of fibrosis in chronic hepatitis C patients. Clin Mol Hepatol. 2020;26:60‐9. https://doi.org/10.3350/cmh.2019.0051

Zhang X, Li HM, Liu Z, Zhou G, Zhang Q, Zhang T, Zhang J, Zhang C. Loss of heterozygosity and methylation of multiple tumor suppressor genes on chromosome 3 in hepatocellular carcinoma. J Gastroenterol. 2013;48:132-43. https://doi.org/10.1007/s00535-012-0621-0

Lv X, Ye G, Zhang X, Huang T. p16 Methylation was associated with the development, age, hepatic viruses infection of hepatocellular carcinoma, and p16 expression had a poor survival: A systematic meta-analysis (PRISMA). Medicine (Baltimore). 2017;96:e8106. https://doi.org/10.1097/MD.0000000000008106

Pawlotsky JM. Hepatitis C virus resistance to antiviral therapy. Hepatology. 2000a;32(5):889-96. https://doi.org/10.1053/jhep.2000.19150

Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR, Schmidt WE, Kallinowski B, Klinker H, Spengler U, Martus P, Alshuth U, Zeuzem S. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006;130:1086-97. https://doi.org/10.1053/j.gastro.2006.02.015

Fried MW, Hadziyannis SJ. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. Semin Liver Dis. 2004;2:47-54. https://doi.org/10.1055/s-2004-832928

Huang Y, Wei L, Zhao RC, Liang WB, Zhang J, Ding XQ, Li ZL, Sun CJ, Li B, Liu QY, He JY, Yu XQ, Gao B, Chen MM, Sun AM, Qin Y. Predicting hepatocellular carcinoma development for cirrhosis patients via methylation detection of heparocarcinogenesis-related genes. J Cancer. 2018;9:2203-10. https://doi.org/10.7150/jca.24024

Shen L, Ahuja N, Shen Y, Habib NA, Toyota M, Rashid A, Issa JP. DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst. 2002;94:755-61. https://doi.org/10.1093/jnci/94.10.755

Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol. 1997;15:797-819. https://doi.org/10.1146/annurev.immunol.15.1.797

Nishikawa Y, Kajiura Y, Lew JH, Kido JI, Nagata T, Naruishi K. Calprotectin Induces IL-6 and MCP-1 Production via Toll-Like Receptor 4 Signaling in Human Gingival Fibroblasts. J Cell Physiol. 2017;232:1862-71. https://doi.org/10.1002/jcp.25724

Lu H, Han M, Yuan X, Tursun K, Zhang Y, Li Y, Li Z, Feng S, Zhou L, Pan Z, Wang Q, Han K, Liu S, Cheng J. Role of IL-6-mediated expression of NS5ATP9 in autophagy of liver cancer cells. J Cell Physiol. 2018;233:9312-9. https://doi.org/10.1002/jcp.26343

Pavón-Castillero EJ, Muñoz-de-Rueda P, López-Segura R, Gila A, Quiles R, Muñoz-Gámez JA, Carazo A, Martínez P, Ruiz-Extremera A, Salmerón J. Importance of IL-10 and IL-6 during chronic hepatitis C genotype-1 treatment and their relation with IL28B. Cytokine. 2013;61:595-601. https://doi.org/10.1016/j.cyto.2012.10.009

Yi M, Wang W, Chen S, Peng Y, Li J, Cai J, Zhou Y, Peng Q, Ban Y, Zeng Z, Li X, Xiong W, Li G, Xiang B. Dual-functionality of RASSF1A overexpression in A375 cells is mediated by activation of IL-6/STAT3 regulatory loop. Mol Biol Rep. 2018;45:1277-87. https://doi.org/10.1007/s11033-018-4288-3

Downloads

Published

2022-04-01

How to Cite

1.
Kokanov NS, Krajnović MM, Jovanović-Ćupić SP, Kožik BR, Petrović NM, Božović AM, Mandušić VL. RASSF1A and p16 promoter methylation and treatment response in chronic hepatitis C genotype 1b patients treated with pegylated interferon/ribavirin. Arch Biol Sci [Internet]. 2022Apr.1 [cited 2022Jul.6];74(1):57-66. Available from: https://www.serbiosoc.org.rs/arch/index.php/abs/article/view/7311

Issue

Section

Articles

Most read articles by the same author(s)